Bcl-6

Choose Selective Bcl-6 Inhibitors

Bcl-6 Products

  • All (4)
  • Bcl-6 Inhibitors (4)
  • New Bcl-6 Products
Catalog No. Product Name Information Product Use Citations Product Validations
S6937 BI-3802 BI-3802 is a highly potent oncogenic transcription factor BCL6 degrader with strong de-repression of target genes anti-proliferative effects. BI-3802 inhibits the BTB domain of BCL6 with IC50 of ≤3 nM. BI-3802 exhibits antitumor activity.
S8250 79-6 (CID5721353) 79-6 (CID5721353) (BCL6 inhibitor) is a BCL6 inhibitor with Kd value of 138 μM.
S8591 FX1 FX1 is a selective BCL6 BTB inhibitor with an IC50 value of 35 μM in reporter assays. FX1 shows great selectivity against a panel of 50 different kinases. 10 μM FX1 fails to significantly inhibit of any of these kinases. FX1 induces apoptosis.
Nat Immunol, 2021, 22(6):757-768
Invest New Drugs, 2021, 10.1007/s10637-021-01196-1
Blood Adv, 2021, bloodadvances.2021005682
S8735 BI-3812 BI-3812 is a highly potent and efficacious BCL6 inhibitor probe compound with an IC50 less than 3 nM.
S6937 BI-3802 BI-3802 is a highly potent oncogenic transcription factor BCL6 degrader with strong de-repression of target genes anti-proliferative effects. BI-3802 inhibits the BTB domain of BCL6 with IC50 of ≤3 nM. BI-3802 exhibits antitumor activity.
S8250 79-6 (CID5721353) 79-6 (CID5721353) (BCL6 inhibitor) is a BCL6 inhibitor with Kd value of 138 μM.
S8591 FX1 FX1 is a selective BCL6 BTB inhibitor with an IC50 value of 35 μM in reporter assays. FX1 shows great selectivity against a panel of 50 different kinases. 10 μM FX1 fails to significantly inhibit of any of these kinases. FX1 induces apoptosis.
Nat Immunol, 2021, 22(6):757-768
Invest New Drugs, 2021, 10.1007/s10637-021-01196-1
Blood Adv, 2021, bloodadvances.2021005682
S8735 BI-3812 BI-3812 is a highly potent and efficacious BCL6 inhibitor probe compound with an IC50 less than 3 nM.
Tags: Bcl-6 Apoptosis | Bcl-6 Immunity | Bcl-6 Inflammatory response | Bcll-6 Transcription | Bcl-6 regulation | Bcl-6 Inhibiton